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FROM THE EDITOR
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T

he purpose of cancer screening is early detection,
which hopefully leads to early cancer prevention/
treatment, curability, or at least risk reduction.
Cancer screening may be defined as a comprehensive
approach to risk stratification that includes patient history,
physical examination, social and family history, and
recommended testing. Often, however, cancer screening
refers to a single modality such as mammography (and
newer imaging systems) or colonoscopy (and various
stool sample testing options). More sophisticated
methods to potentially evaluate screening for multiple
cancers using molecular platforms are currently being
researched.1 Examples include the Galleri™ assay
(GRAIL, now part of Illumina, Inc.), for which the
United Kingdom’s National Health Services launched a
clinical trial targeting 140,000 volunteers in September
2021, and CancerSEEK (Exact Sciences Thrive LLC).2-4
While continuous advances in cancer screening
techniques keep the industry and health care providers on
their toes, contemporary practices generally rely on a few
staples. We know that ascertaining an accurate family
history can identify potential genetic predispositions
to cancer. However, in time- and resource-constrained
clinical offices, the status of family history collection,
documentation, and actionability often are not optimal.5
Genetic counseling referrals are encouraged but may be
underutilized for a variety of reasons, including access
(location and cost) and genetic counselor availability
in some health systems.5 Approaches are needed to
increase the supply of genetic counselors in number and
access. This may include increased training programs,
telegenetics, and algorithm-assisted identification of
patients for increased genetic assessment.6,7
We also know that frequency of cancer screening depends
in part on access to health care. During the COVID-19
pandemic, the Centers for Disease Control and Prevention
reported 80% declines in screenings for breast and
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cervical cancer.8,9 Unger
and colleagues showed that
there was a “… precipitous
decrease in enrollments during
the initial COVID-19 wave,
but only a modest reduction
during the winter 2020-2021
wave.10 Over the entire year,
steep enrollment reductions
were found for cancer
control and prevention trials,
whereas for treatment trials,
enrollments were similar to expected rates.” The authors
further noted that “these findings suggest that clinical trial
research rapidly adapted to the circumstances of enrolling
and treating patients on protocols during the COVID-19
pandemic.”10 Future studies will further examine screening
trends in the pandemic’s aftermath (recognizing that end is
currently not defined). There have been calls for “applying
a pandemic-like response to cancer prevention.”11 This
could include utilizing personalization (as with precision
medicine) or artificial intelligence.12
While some screening methods have not been useful —
eg, chest X-ray for lung cancer13 or CA125 testing for
ovarian cancer14 — others have been tested rigorously and
been found to have utility, such as computed tomography
lung cancer screening in specific populations.15,16
In this theme issue of the Journal of Patient-Centered
Research and Reviews (JPCRR), multiple articles delve
into a range of cancer prevention topics. Brady et al
qualitatively evaluated barriers to and promoters of cancer
screening.17 The same authorship group implemented
quality improvement strategies over 7 years in an effort
to increase cancer screening rates in safety-net primary
care practices.18 In a pair of research studies, Saman et al
gleaned patient perceptions of clinical decision support
tools targeting cancer prevention,19 while Schrager et
al evaluated the effect of shared decision-making and
other patient and clinician characteristics on breast
cancer screening rates for women in their 40s.20 Schad
et al reported the negative, but variable, impact of the
COVID-19 pandemic on breast, cervical, and colorectal
cancer screening rates in primary care settings,21 and El
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Khoury et al researched patients’ potential willingness
to overcome some of this disruption through expanded
utilization of home-based screening tests for colorectal
cancer and cervical cancer.22 Among the remaining articles
published within this issue of JPCRR, a topic synopsis on
genetic testing for familial hypercholesterolemia shares
insights that could also be applied to improving testing
for genetic risk in the cancer setting.23
There remains much to be learned about how we can
best use screening measures, both old and new, to detect
malignancies as early as possible without unnecessarily
wasting valuable time and resources. The works reported
herein add to the ongoing discussions around how to
prevent and control cancer for maximal patient benefit
while improving the cost of cancer care both in “normal”
times and in the context of a pandemic.
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